Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00836537 | Benazepril HCl 40 mg Tablets, Fed | PHASE1 | COMPLETED | 40 | — | — | Mar 1, 2001 | Mar 1, 2001 | May 12, 2023 | 1 | United States |
| NCT00836576 | Benazepril HCl 40 mg Tablets, Fasting | PHASE1 | COMPLETED | 40 | — | — | Feb 1, 2001 | Mar 1, 2001 | Aug 19, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Benazepril HCl 40 mg Tablets | DRUG | 1 x 40 mg, single-dose fed |
| Lotensin® 40 mg Tablets | DRUG | 1 x 40 mg, single-dose fed |
Inclusion Criteria: * Screening Demographics: All volunteers for selected for this study will be healthy men or women 19 years of age or older at the time of dosing. The weight range will not exceed ±20% for height and body frame as per Desirable Weights for Men - 1983 Metropolitan height and Weigh...